We guide biotech, healthcare, medtech, and pharmaceutical enterprises—public and private, large and small—in solving their legal problems at every stage of growth. We offer experienced guidance through the sector’s complex regulatory, transactional, operational, financial, and compliance issues and disputes.
Life sciences and healthcare organizations depend on experienced representation in business, legal, and regulatory matters. Our biotechnology and pharmaceutical teams support clients developing and commercializing products and services that diagnose, prevent, and treat disease. We also advise clients in the medical device and medtech sectors on technologies spanning cardiovascular, diabetes, gastroenterology, imaging systems, implants, neurology, optics, pain management, renal care, stimulation devices, and surgical tools.
We are an innovation partner to clients, helping them grow from the ground up to publicly traded Fortune 500 companies. Our lawyers counsel clients on intellectual property matters, fundraising, strategic alliances, collaborations, licenses, and other technology transactions, beginning with early-stage companies.
We advise healthcare providers and organizations, hospitals, insurers, research institutions, and companies throughout the industry on digital health services, FDA and controlled substance issues, transactions, managed care, litigation, operations and policy, regulatory compliance, reimbursement, data privacy and security, contracts and associated disputes, internal investigations, government audits and investigations, antitrust, tax, M&A, and real estate.
Our IP team offers boutique capabilities within a global, full-service firm. With a proven track record, we represent pharmaceutical and biotechnology clients in complex, high-stakes patent litigation in federal district courts across the United States and before the U.S. Court of Appeals for the Federal Circuit and U.S. International Trade Commission. We guide clients through inter partes review, ex parte reexamination, derivation, and interference proceedings before the U.S. Patent Trial and Appeal Board (PTAB), and we prosecute and manage patent portfolios. Furthermore, we counsel pharmaceutical companies on regulatory strategies and all aspects of the Hatch-Waxman Act and Biologics Price Competition and Innovation Act (BPCIA). Our global presence allows us to assemble strong teams around the world.
Industry and technical strength
Our lawyers know the industry, as well as the laws and regulations that apply to it. Many of our life science lawyers have advanced degrees in various disciplines of biology, chemistry, engineering, and computer science.
Strategic advice
Ashurst Perkins Coie’s teams of lawyers, patent agents, and science advisers understand the inherent challenges of clients’ collective mission to cure disease and improve people’s health, as well as the regulations that govern these pursuits.
Advanced industry knowledge
Our areas of focus span a broad range of cutting-edge life sciences and health tech technologies. These include AI-based diagnostics and drug discovery, next-generation antibody therapeutics, biologics and biosimilars, cancer diagnostics, therapeutics, vaccines, cellular therapeutics, gene editing and gene therapy, cfDNA diagnostics and NIPT, CAR-T, T-cell receptor therapy, next-generation and third-generation sequencing, peptide therapeutics, and small molecule therapeutics.
Related insights
Carousel: clicking the "Previous" or "Next" button changes the content between the buttons.
-
Legal development
Enhancing Director ID Requirements
August 10, 2026
Discover more -
Legal development
Ashurst Perkins Coie Governance & Compliance Update – Issue 85
August 07, 2026
Discover more -
Legal development
Competing interests: Arbitration clauses & winding-up proceedings in common law jurisdictions
August 07, 2026
Discover more -
Business Insight
The Insider Threat: Critical Infrastructure's Overlooked Vulnerability
August 06, 2026
Discover more -
Legal development
Foreign Powers of Attorney in German Notarial Transactions
August 03, 2026
Discover more -
Legal development
Key takeaways from the fifth UK NSIA Annual Report
July 31, 2026
Discover more -
Legal development
EFRAG consults on proposed sustainability reporting standards for non-EU companies
July 30, 2026
Discover more -
Legal development
Adjudication risks: Email file-share links may not constitute service under WA's SOPA
July 28, 2026
Discover more -
Risk Insight
Automated decisions in Australia series – Part 2: Learnings from the regulator’s consultation paper
July 27, 2026
Discover more -
Legal development
Swift & simple: UK consultation on competition law reforms
July 24, 2026
Discover more -
Legal development
The FCO 2025/26 Review: What's Next for German Antitrust Enforcement
July 23, 2026
Discover more -
Legal development
ECJ rules on FIFA Agent Regulations' compatibility with EU competition law
July 23, 2026
Discover more
Related news
View allCarousel: clicking the "Previous" or "Next" button changes the content between the buttons.